Bayer Launches Phase 4 Study Testing Switch from Tafamidis to Acoramidis in ATTR-CM Patients
核心洞察
Bayer has initiated a Phase 4 study evaluating the switch from tafamidis to acoramidis in patients with transthyretin amyloid cardiomyopathy (搜索) (ATTR-CM (搜索)).
The single-arm study aims to measure changes in serum transthyretin (搜索) levels when patients transition from Pfizer's tafamidis to Bayer's acoramidis therapy.
Positive results could help Bayer capture market share in the growing rare cardiology segment currently dominated by tafamidis as the standard of care.
Bayer AG has launched a Phase 4 clinical study to evaluate the therapeutic switch from tafamidis to acoramidis in patients with transthyretin amyloid cardiomyopathy (搜索) (ATTR-CM (搜索)), marking a significant move to challenge Pfizer's dominance in this rare cardiology market.
Study Design and Objectives
The prospective, single-arm study officially titled "A Prospective, Single-arm, Phase 4 Study to Evaluate the Course of Serum Transthyretin (搜索) (TTR) Level With Acoramidis in Adult Patients With Variant or Wild-type Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM (搜索)) Previously Treated With Tafamidis" aims to measure how blood levels of the protein transthyretin change when patients transition between therapies.
The primary goal is to determine if acoramidis can raise and stabilize transthyretin (搜索) levels more effectively than tafamidis, which could signal better disease control and heart function in this serious heart condition. All enrolled patients will receive acoramidis tablets twice daily after discontinuing tafamidis treatment.
Treatment Mechanism and Rationale
Acoramidis, already approved in Europe and the United States for both wild-type and variant ATTR-CM (搜索), works by stabilizing the transthyretin (搜索) protein to prevent it from forming harmful deposits in the heart. The study design is open-label with no randomization or placebo arm, focusing on treatment outcomes rather than comparative efficacy.
Current Status and Timeline
The trial is listed as not yet recruiting, with initial submission on December 11, 2025, and the latest update filed on January 8, 2026. This indicates the protocol and operational plans are still being refined ahead of first patient enrollment. As a Phase 4 study, primary completion and final completion dates have not yet been specified in the public record.
Market Implications
The study represents Bayer's strategic push to deepen its presence in the ATTR-CM (搜索) market, where tafamidis has been the long-standing standard of care. Positive results showing superior biomarker effects after switching from tafamidis to acoramidis could support stronger positioning for acoramidis in both new and existing patients, helping Bayer capture share in the growing rare-cardiology segment.
If differences in transthyretin (搜索) levels prove modest, competitive pressure on incumbents like Pfizer may remain limited, and acoramidis uptake could depend more on pricing and access negotiations than clear clinical differentiation. The study could improve sentiment around Bayer's late-stage and post-approval cardiovascular pipeline, particularly if payers and guidelines eventually favor acoramidis over tafamidis in certain patient groups.